News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

|Videos|April 5, 2023

Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

Author(s)Kathryn E. Beckermann, MD, PhD, Moshe Ornstein, MD, MA, Mehmet Asim Bilen, MD

The panel provides an overview of novel double combination therapies currently under investigation.

Episodes in this series

EP. 1 Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP. 1 Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP. 2 Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

EP. 3 Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP. 3 Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP. 4 Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP. 4 Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP. 5 Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP. 5 Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP. 6 Treatment Approaches for Patients with RCC and Bone Metastases

EP. 6 Treatment Approaches for Patients with RCC and Bone Metastases

EP. 7 Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP. 7 Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP. 8 Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP. 8 Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP. 9 Updates in the Adjuvant Treatment of Metastatic RCC

EP. 9 Updates in the Adjuvant Treatment of Metastatic RCC

$EP. 10 Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC$

EP. 10 Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

$EP. 11 Preferred Treatment Regimens for Refractory RCC$

EP. 11 Preferred Treatment Regimens for Refractory RCC

EP. 12 Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP. 12 Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP. 13 Genetic Counseling for Patients with Non-Clear Cell RCC

EP. 13 Genetic Counseling for Patients with Non-Clear Cell RCC

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Toni Choueiri, MD, Dana-Farber Cancer Institute

July 1st, 2026

FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC

Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

T-DXd for HER2+ Solid Tumors | Image Credit: © Rasi - stock.adobe.com

June 29th, 2026

T-DXd Wins EU Approval for Previously Treated, HER2+ Metastatic Solid Tumors

The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.

Trending on OncLive

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases

Neoadjuvant/Adjuvant Pembrolizumab Yields EFS Benefits Regardless of Surgical Outcomes in HNSCC